For patients with heart failure (HF), a greater focus on medication management may be needed in order to mitigate HF exacerbations caused by certain ...

A recent analysis from a randomized clinical trial conducted by researchers at the Dana-Farber Brigham Cancer Center ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on NTRA stock, giving a Buy rating yesterday.Invest with Confidence: ...

A study finds that celecoxib improves disease-free survival in stage 3 colon cancer patients with positive ctDNA after ...

An analysis of ctDNA testing for early detection of recurrence showed that test had high sensitivity across multiple sites of ...

Natera has reported the latest data from the Phase III CALGB (Alliance)/SWOG 80702 study, indicating that Signatera, a ...

In addition to ZTlido, Scilex's portfolio features Elyxyb, an oral celecoxib solution for migraines, which may also find broader use for acute pain such as tension headaches. Another product ...

The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced new data from the randomized, ...